March 6, 2017 / 2:22 PM / 5 months ago

BRIEF-Exelixis' cabozantinib granted orphan drug designation

1 Min Read

March 6 (Reuters) - Exelixis Inc

* Exelixis' cabozantinib granted orphan drug designation for the treatment of hepatocellular carcinoma

* Exelixis inc - exelixis has guided that data from trial are expected in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below